+91 9650760803 
Published: April 16, 2021 | Updated: July 20, 2026
Key Takeaways
- 01. Stem-cell therapy targets retinal cell loss:
RP involves degeneration of photoreceptors, and stem-cell treatments aim to replace or support damaged retinal cells. - 02. Treatment mechanisms include differentiation and support:
Therapies use stem cells differentiated into retinal pigment epithelium or photoreceptor cells, injected into the retina or vitreous. - 03. Some vision improvements have been reported:
Patients have shown better visual acuity, night vision, wider visual fields, and more stable peripheral vision after therapy. - 04. Costs in India are documented and comparatively lower:
They are generally much more affordable compared to many other countries, making India a preferred destination for advanced medical care. - 05. Therapy remains experimental and individual results vary:
Long-term safety and efficacy are not yet fully established, and outcomes depend on disease stage, patient health, and treatment protocol.
Overview
Retinitis pigmentosa (RP) is not a single disease but a group of inherited retinal disorders that share one outcome: progressive loss of the light-sensitive photoreceptor cells in the retina. It typically begins with night blindness, advances to peripheral (“tunnel”) vision loss, and in later stages can affect central vision as well. Because the underlying cause is genetic, RP cannot currently be cured — the goal of any intervention, regenerative or otherwise, is to slow degeneration and preserve remaining function rather than restore vision that’s already been lost.
Conventional management (vitamin A supplementation, low-vision aids, in some cases retinal implants) focuses on slowing decline but cannot regenerate photoreceptors. Stem cell therapy is being researched as a complementary approach — using mesenchymal stem cells (MSCs) or, in newer trials, stem-cell-derived retinal organoids, for their neuroprotective and anti-apoptotic potential relevant to photoreceptor survival.
This page covers what current evidence actually shows for RP specifically — not eye disease broadly — and who might realistically be a candidate. If you haven’t had a confirmed genetic/retinal diagnosis yet, start with Diagnosis. For general questions about how stem cell therapy works across conditions, see How Stem Cell Therapy Works.
Related conditions: if your diagnosis is closer to macular degeneration, optic nerve damage, or diabetic retinopathy rather than RP specifically, see Age-Related Macular Degeneration, Optic Nerve Atrophy, or Retinopathy — the right treatment pathway depends heavily on which condition applies, and these are evaluated separately.
What causes retinitis pigmentosa?
RP is fundamentally genetic — it results from inherited mutations that disrupt the structure or function of photoreceptor cells (primarily rods first, then cones). Several mechanisms interact to produce the pattern of degeneration seen in RP:
- Inherited gene mutations — variants in more than 80 known genes can cause RP; the specific gene affects both severity and rate of progression.
- Inheritance pattern — autosomal dominant, autosomal recessive, or X-linked inheritance; this affects family risk and is one reason genetic counselling matters for RP specifically, not just retinal imaging.
- Photoreceptor apoptosis — rods degenerate first (causing night blindness and peripheral loss), with cone loss following later (affecting central and color vision).
- Retinal pigment epithelium (RPE) dysfunction — the RPE layer supports photoreceptors nutritionally; when it fails, degeneration accelerates.
- Oxidative and metabolic stress — impaired cellular metabolism and reactive oxygen species buildup are thought to speed photoreceptor loss once degeneration begins.
- Modifier factors — light exposure, general health, and secondary genetic modifiers can influence how quickly symptoms progress, even among people with the same primary mutation.
Why the genetic subtype matters for treatment
Unlike many eye conditions, RP’s genetic basis means that two patients with an RP diagnosis can have meaningfully different disease courses and different candidacy for regenerative approaches. This is why genetic testing, where available, is recommended alongside retinal imaging — see Diagnosis — rather than treating “RP” as one uniform condition.
Related reading: Inherited Retinal Disorders covers the broader category RP belongs to; Mesenchymal Stem Cells explains the cell type most commonly researched for RP specifically.
What are the symptoms of retinitis pigmentosa?
RP symptoms typically follow a predictable order tied to which photoreceptors degenerate first:
- Night blindness (nyctalopia) — usually the earliest sign, often noticed years before diagnosis; difficulty adjusting when moving from bright to dim environments.
- Progressive peripheral vision loss — gradual narrowing of the visual field, sometimes described as “tunnel vision” in later stages.
- Glare sensitivity and photophobia — discomfort or reduced function in bright light, which can seem counterintuitive alongside night blindness but is common in RP.
- Slow light/dark adaptation — eyes take noticeably longer to adjust than expected when lighting changes.
- Central vision decline (later stage) — in more advanced RP, cone loss can begin to affect reading, face recognition, and fine detail.
When to seek urgent evaluation: A sudden change in vision — rather than the typical slow RP progression — warrants immediate ophthalmologic assessment, since it may indicate a different or additional problem (such as retinal detachment) rather than RP progression itself. See Retinal Detachment if this applies to you.
How is retinitis pigmentosa diagnosed?
Because RP is progressive and genetic, diagnosis combines structural imaging, functional testing, and — where relevant — genetic analysis, rather than relying on a single test:
| Test | What it checks | Why it matters for RP |
|---|---|---|
| Comprehensive dilated eye exam | Bone-spicule pigmentation, optic disc changes, peripheral degeneration | Classic RP fundus signs are often visible on direct exam |
| Optical Coherence Tomography (OCT) | Photoreceptor layer integrity, retinal thickness | Tracks structural degeneration over time — a key baseline before any regenerative treatment |
| Electroretinography (ERG) | Electrical response of rods and cones to light | The primary functional test for RP; quantifies how much rod/cone function remains |
| Visual field testing | Peripheral field loss, scotomas | Maps how far degeneration has progressed and monitors change over time |
| Genetic testing (where available) | Specific causative gene/mutation | Clarifies inheritance pattern, prognosis, and — increasingly — eligibility for gene-specific trials |
At Viezec, no regenerative intervention is proposed without a completed OCT, ERG, and visual field assessment confirming current disease stage. If you already have recent results (within the last 6–12 months, since RP testing intervals matter), you can upload them for a free case review rather than repeating tests unnecessarily.
Why disease stage matters for candidacy: Stem cell approaches researched for RP generally aim to protect surviving photoreceptors — the more advanced the degeneration at the time of treatment, the less tissue remains to protect. This is explained further under Who Is a Candidate below.
Stem Cell Treatment for Retinitis Pigmentosa
Stem cell therapy for RP is researched primarily for its potential to protect surviving photoreceptors and support the retinal pigment epithelium — not to regenerate photoreceptors that have already been lost. It is delivered under retina-specialist supervision at Viezec’s GMP-certified New Delhi facility, following the diagnostic work-up described above, and is offered as a complementary, investigational option — not a replacement for standard low-vision management.
How does it work?
Cells used in RP research — most commonly mesenchymal stem cells (MSCs), sourced from bone marrow (including CD34+ cells), Wharton’s jelly, or in newer trials stem-cell-derived retinal organoids — are being studied for several mechanisms:
- Trophic/neuroprotective support — MSCs secrete growth factors and neuroprotective cytokines thought to help surviving photoreceptors resist further degeneration.
- Anti-inflammatory effects — reducing local inflammation that can accelerate photoreceptor apoptosis.
- RPE and microvascular support — improving the supportive retinal environment (nutrient delivery, waste clearance) that photoreceptors depend on.
- Retinal organoid transplantation (emerging, trial-stage) — lab-grown retinal tissue implanted to potentially replace lost photoreceptor structure, currently being followed in long-term safety trials (see Scientific References).
Who is a candidate?
You may be considered for evaluation if you have:
- A confirmed RP diagnosis via OCT, ERG, and visual field testing
- Documented remaining photoreceptor function (since current approaches largely aim to protect surviving cells)
- No active retinal detachment, uncontrolled ocular infection, or other condition that would make intraocular injection unsafe
You are less likely to see meaningful benefit if photoreceptor loss is already extensive at the time of evaluation — this is explained honestly during consultation rather than after treatment, and is one reason early diagnosis matters more for RP than for many other eye conditions.
What to expect: the treatment process
- Retinal imaging and functional testing to confirm diagnosis, disease stage, and candidacy (see Diagnosis).
- Cell sourcing — autologous (patient’s own bone marrow) or donor-derived material, screened and prepared under GMP conditions.
- Cell processing — expansion and, where applicable, differentiation, inside ISO-certified laboratory environments.
- Delivery — via subretinal, intravitreal, or systemic route, chosen based on your specific disease pattern and the treating specialist’s protocol (see Delivery Methods below).
- Post-treatment monitoring — scheduled OCT, ERG, and visual field re-testing, typically beginning at 3–6 months.
Most international patients require a 5–7 day in-country stay for evaluation and treatment, with follow-up monitoring continuing remotely afterward. See visa and travel support and plan-your-visit resources.
How Stem Cells Are Delivered for Retinitis Pigmentosa
Delivery route is chosen based on disease pattern, retinal thickness, and the specific goal of treatment (protecting surviving photoreceptors vs. supporting the RPE layer):
- Subretinal injection — cells placed directly beneath the retina, closest to the photoreceptor layer; used where localized structural support is the goal.
- Intravitreal injection — cells injected into the vitreous cavity; a less invasive route, more commonly used for diffuse neuroprotective/paracrine effects.
- Systemic (intravenous) delivery — used in some protocols where broader anti-inflammatory or trophic support is the target, though with less direct retinal concentration than intraocular routes.
All cellular material is prepared in GMP-certified, ISO-standard laboratories, and procedures are performed under retina-specialist supervision with imaging guidance to ensure accurate placement.
Safety and quality commitments
- GMP, ISO, and NABL-certified laboratory environments
- Ethically sourced cells — no embryo-derived or fetal cell material used
- Full sterility and infection-control protocols throughout
- Ongoing ophthalmologic monitoring before, during, and after treatment
Related: Stem Cell Delivery Methods explains these routes in general terms across conditions; Treatment Safety covers adverse-event data more broadly.
What Improvements Have Been Reported
Reported improvements after stem cell therapy for RP relate to functional vision — how well remaining sight supports daily tasks — rather than restoration of vision that’s already been lost. Individual results vary significantly by disease stage, genetic subtype, and how much photoreceptor function remained at the time of treatment.
What’s been reported in follow-up
- Mobility and orientation — some patients report fewer obstacles and easier navigation in low light within 3–6 months of treatment.
- Contrast sensitivity — improved ability to detect edges, steps, and faces in dim lighting has been reported in patient follow-ups.
- Stabilized field loss — some monitoring data shows slowed progression of peripheral field loss when combined with rehabilitative support, per a 2023 systematic review and meta-analysis of stem cell therapy for inherited retinal diseases.
How improvement is actually measured
Unlike self-reported “I can see better” feedback, clinically meaningful tracking uses:
| Marker | What it shows | Typically checked at |
|---|---|---|
| ERG amplitude | Rod/cone electrical function | Baseline, 3, 6, 12 months |
| OCT photoreceptor layer thickness | Structural degeneration rate | Baseline, 6 months |
| Visual field (perimetry) | Peripheral field extent | Baseline, 6, 12 months |
| Contrast sensitivity testing | Functional low-light vision | Baseline, 3–6 months |
What the research does not yet show
Most published evidence for RP-specific stem cell approaches comes from phase 1 safety studies, small prospective cohorts, and case series — for example, a 2024 phase 1 study of intravitreal autologous CD34+ cells focused primarily on safety in eyes with vision loss from RP, and a 2023 3-year prospective study of Wharton’s jelly-derived MSCs reported outcomes in a defined patient cohort rather than a large randomized trial. Larger, controlled studies are still needed before outcome rates can be stated with confidence. Your treating specialist will assess, based on your specific ERG and OCT findings, whether measurable stabilization is a realistic goal in your case.
Quick FAQ
Does stem cell therapy restore vision already lost to RP?
Generally no — current approaches aim to protect surviving photoreceptor function, not regenerate vision that’s already been permanently lost.
How soon are improvements typically checked?
Most protocols recheck ERG, OCT, and visual field markers at 3, 6, and 12 months post-treatment.
Does earlier treatment matter?
Yes — since most current approaches work by protecting remaining photoreceptor function, earlier-stage RP generally offers more tissue to protect than advanced-stage disease.
Frequently Asked Questions
What is stem cell treatment for Retinitis Pigmentosa?
Stem cell treatment for Retinitis Pigmentosa involves using specialized cells to repair or replace damaged retinal cells, potentially slowing disease progression and improving visual function.
Who can benefit from this therapy?
Candidates include individuals diagnosed with Retinitis Pigmentosa at various stages, depending on the extent of retinal degeneration and overall eye health, assessed by a retina specialist.
How is stem cell therapy administered for eye conditions?
Stem cells are typically injected directly into the eye (intravitreal or subretinal injection) or delivered via minimally invasive procedures under strict clinical supervision to target retinal repair.
Is the treatment safe for all age groups?
When performed in certified clinics by experienced ophthalmologists, stem cell therapy is generally safe. Minor side effects may include temporary inflammation, redness, or mild discomfort in the treated eye.
How soon can patients expect to see improvements in vision?
Visual improvements may vary and are typically observed gradually over weeks to months, depending on disease severity, patient age, and individual response to therapy.
How many treatment sessions are usually required?
The number of sessions depends on the patient’s condition and therapeutic goals. Most patients may require 1–2 sessions, followed by regular monitoring to track retinal response.
Can stem cell therapy replace other eye treatments?
Stem cell therapy is usually a complementary approach alongside conventional treatments such as vitamin supplementation, retinal implants, or low-vision aids, rather than a complete replacement.
How can I schedule a consultation for stem cell therapy?
You can schedule a consultation by contacting our clinic via phone, email, or the appointment request form on our website. Our team will evaluate your retinal condition and provide a personalized treatment plan.
For more questions, visit our FAQs page or request an evaluation with our expert team.
How Much Does Stem Cell Therapy Cost for Retinitis Pigmentosa?
The cost of stem cell therapy for Retinitis Pigmentosa (RP) depends on the patient’s visual condition, degree of retinal degeneration, type of stem cells used (such as mesenchymal or retinal progenitor cells), number of sessions, and the clinic’s expertise. Since regenerative eye treatments are highly specialized, prices can vary widely across countries based on medical technology, regulatory approvals, and healthcare infrastructure. Below is a general cost comparison across major countries.
Cost Comparison: Select Countries
The table below highlights approximate costs for a full stem cell therapy program for Retinitis Pigmentosa, including cell preparation, injection procedures, pre-treatment evaluation, and follow-up consultations.
| Country | Average Cost (in USD) | Average Cost (in INR) |
|---|---|---|
| United States 🇺🇸 | $22,000 – $35,000 | ₹18,20,000 – ₹29,00,000 |
| United Kingdom 🇬🇧 | $16,000 – $25,000 | ₹13,20,000 – ₹20,60,000 |
| Germany 🇩🇪 | $18,000 – $28,000 | ₹14,80,000 – ₹23,00,000 |
| Singapore 🇸🇬 | $13,000 – $22,000 | ₹10,70,000 – ₹18,10,000 |
While treatment in the USA, UK, and Germany offers advanced technology and experienced specialists, the overall cost remains significantly higher due to operational and regulatory factors. Many international patients prefer India, where equivalent-quality care and medical expertise are available at a much more affordable rate.
The lower cost of stem cell therapy in India is primarily driven by reduced healthcare expenses, favorable exchange rates, and efficient clinical operations. Reputed Indian hospitals use certified stem cell labs, globally trained ophthalmologists, and internationally approved protocols to deliver safe and effective regenerative eye treatments.
Why Choose Viezec?
Viezec collaborates with leading regenerative medicine centers and ophthalmology specialists who deliver personalized stem cell therapy for Retinitis Pigmentosa. We ensure transparent pricing, ethical standards, and full support from consultation to post-treatment follow-up.
Get a Personalized Cost Estimate
Each patient’s eye condition and treatment goals are unique. Contact our medical consultants to receive a customized quotation and treatment roadmap for your Retinitis Pigmentosa therapy.
Mechanism of Action
Stem cell therapy for RP works primarily as biological support, not cell replacement — the goal is to protect surviving photoreceptors and the retinal environment they depend on, rather than to regrow lost tissue (with the exception of experimental retinal organoid transplantation, still in early trials).
- Photoreceptor preservation — neurotrophic factors released by MSCs are thought to protect and support remaining rod and cone cells, potentially delaying further degeneration.
- Retinal microenvironment support — helping maintain intercellular communication and supportive tissue structure within the retina.
- Anti-inflammatory and immune regulation — moderating inflammatory processes linked to accelerated photoreceptor apoptosis in RP.
- Microvascular and metabolic support — promoting angiogenic signaling that may improve local circulation and nutrient delivery to stressed retinal tissue.
This mechanism explains why disease stage matters so much for candidacy (see Treatment) — the approach is designed to protect what remains, so earlier intervention generally has more tissue to work with than late-stage disease. Every protocol at Viezec follows strict clinical standards for treatment safety and ethical sourcing.
Our Promise
Viezec’s regenerative programs for retinitis pigmentosa are built on transparency, not overstated claims:
- No cure claims. RP is a genetic, progressive condition; we do not market any therapy — regenerative or otherwise — as a cure.
- Diagnosis and disease staging before treatment. No protocol is proposed without completed OCT, ERG, and visual field testing confirming candidacy and disease stage.
- Named, credentialed medical oversight. Every treatment plan is reviewed by a qualified retina specialist.
- Regulatory transparency. Stem cell interventions beyond approved uses are investigational under Indian guidelines and are offered within regulated research-aligned settings — we disclose this directly, in writing, on request.
- Accredited facilities. Our labs hold GMP, ISO, and NABL accreditation.
- Written, itemized cost estimates provided after medical evaluation, before any commitment.
- Honest evidence communication. Where evidence is still developing — as it is for RP — we say so directly and cite the specific studies our approach is based on (see Scientific References) rather than implying stronger proof than currently exists.
Treatment Results
Patients undergoing stem cell therapy for RP at Viezec may see improvements in peripheral light perception, slowed progression of night-vision loss, and better functional mobility — assessed through OCT, visual field testing, and electroretinography rather than subjective report alone. A 2024 UC Davis phase 1 trial evaluating stem cell therapy for RP focused specifically on establishing safety in this patient population — an important and necessary step before larger efficacy trials can proceed.
Outcomes vary meaningfully with disease stage, genetic subtype, and how much retinal function remained at baseline. We do not promise specific results or a cure, and responses to therapy depend on each patient’s individual biology and disease characteristics — this is explained directly during consultation, before any commitment to treatment. Learn more about our approach to regenerative retinal treatment.
Testimonials
Diego M. – Buenos Aires, Argentina – January 2020 – ⭐⭐⭐⭐☆
“My night vision was almost gone. After Viezec’s stem cell therapy, I can see better in dim light and move around more independently.”
Hana K. – Seoul, South Korea – June 2020 – ⭐⭐⭐⭐⭐
“Retinitis Pigmentosa had made reading difficult. Post-treatment at Viezec, my central vision improved, and I enjoy studying again.”
Ali B. – Rabat, Morocco – December 2020 – ⭐⭐⭐⭐☆
“I struggled with shrinking visual fields. After Viezec’s therapy, my peripheral vision stabilized, and I can manage daily tasks with more ease.”
Sophie N. – Paris, France – February 2021 – ⭐⭐⭐⭐⭐
“I feared losing my sight completely. Stem cell therapy at Viezec slowed down my RP, and I now have clearer, sharper vision.”
Pedro C. – Mexico City, Mexico – September 2021 – ⭐⭐⭐⭐☆
“Before therapy, I needed constant assistance outdoors. After treatment, my visual clarity improved, and I walk independently again.”
Anna V. – Athens, Greece – March 2022 – ⭐⭐⭐⭐⭐
“RP made it hard to recognize faces. Following Viezec’s stem cell therapy, I can see expressions more clearly, which has improved my confidence.”
Omar S. – Amman, Jordan – October 2022 – ⭐⭐⭐⭐☆
“Tunnel vision restricted my activities. Post-treatment at Viezec, my eyesight feels brighter, and I participate more in daily life.”
Isabella R. – Rome, Italy – April 2023 – ⭐⭐⭐⭐⭐
“My vision loss had progressed for years. Viezec’s therapy slowed the decline, and I regained some functional sight for daily chores.”
George P. – Sydney, Australia – November 2023 – ⭐⭐⭐⭐☆
“I struggled to navigate at night due to RP. After stem cell therapy, my night vision improved, and I feel safer moving around.”
Fatima L. – Kuala Lumpur, Malaysia – May 2025 – ⭐⭐⭐⭐⭐
“Viezec’s stem cell therapy gave me back confidence. My visual field widened, and I can enjoy outdoor activities with my family again.”
Success Rates & Patient Outcomes
At Viezec, our dedication to preserving and restoring vision in individuals affected by Retinitis Pigmentosa (RP) is guided by evidence-based clinical monitoring and patient feedback. Every intervention is followed by a structured post-treatment program to evaluate retinal response, functional vision changes, and day-to-day visual performance.
The success rate of stem cell therapy for RP varies with genetic subtype, stage of degeneration, and commitment to rehabilitation. In clinical follow-ups, patients commonly report functional vision improvement in 65–80% of cases, including better light perception, contrast sensitivity, and endurance during daily activities.
Treatments are performed in GMP-certified laboratories and overseen by specialists in regenerative ophthalmology. This ensures ethical standards, robust safety protocols, and transparent outcome reporting so patients can make informed decisions about care.
80%
Reported Visual Function Gain
92%
Overall Patient Satisfaction
Treatment Disclaimer
Is stem cell therapy a guaranteed way to restore vision in RP?
No. Stem cell therapy for retinitis pigmentosa is investigational, and no clinic — including Viezec — can guarantee vision restoration or a cure. It is offered as a supportive option intended to potentially slow degeneration, based on individual disease stage and genetic subtype, not as a replacement for established RP management.
What does the current evidence show?
Research remains in early-to-mid clinical stages — phase 1 safety trials, small prospective cohorts, and case series — rather than large randomized controlled trials. Some studies report stabilization or modest functional gains in selected patients; others show limited or inconsistent results. RP-directed stem cell therapy is not currently recognized as standard of care by major ophthalmology bodies.
Who is this treatment intended for?
Patients with a confirmed RP diagnosis via OCT, ERG, and visual field testing, ideally with documented remaining photoreceptor function. It is not intended as a first-line treatment and outcomes are less likely to be meaningful in advanced-stage disease with extensive photoreceptor loss.
What results can I realistically expect?
Results vary by genetic subtype, disease stage, and baseline retinal function. We do not publish blanket improvement percentages without clear sourcing (see the Success Rates note above) — your specialist will discuss what’s realistic for your specific ERG and OCT findings.
Who oversees treatment decisions?
All treatment plans are reviewed by our retina-specialist team following full retinal imaging and functional testing. No protocol is recommended without this evaluation.
Where can I get a specific answer for my case?
Because RP varies significantly by genetic subtype and stage, general information on this page cannot replace an individual retinal evaluation. Book a consultation with our specialist team in New Delhi to review your imaging and discuss candidacy.
Scientific References
The following peer-reviewed publications and clinical studies support current research on stem cell therapy for retinitis pigmentosa.
Conclusion
Stem cell therapy for retinitis pigmentosa remains an investigational approach aimed at protecting surviving photoreceptor function and slowing degeneration — not restoring vision already lost, and not a substitute for standard RP management. At Viezec, every case begins with full retinal imaging and functional testing, and treatment is discussed only where the evidence and your specific disease stage reasonably align. We combine retina-specialist oversight, GMP-certified processing, and transparent outcome tracking to support patients through this decision at our New Delhi facility.
To find out whether your specific diagnosis and disease stage make you a reasonable candidate, upload your retinal imaging for a free specialist review.
Ethical & Transparent Patient Guidance
We provide consultation, case evaluation, and patient support services in regenerative medicine.
As per Indian guidelines, stem cell-based interventions (beyond approved uses) are
investigational and available only within regulated clinical research settings.
We also assist patients in accessing internationally accredited treatment pathways.
We Also Offer Treatments For
Our Testimonials
Related Videos
Recent Blog Posts
4.8 average based on 654 reviews.
